nodes	percent_of_prediction	percent_of_DWPC	metapath
Arformoterol—CYP2A6—Fluorouracil—urinary bladder cancer	0.132	0.551	CbGbCtD
Arformoterol—CYP2C9—Fluorouracil—urinary bladder cancer	0.0454	0.19	CbGbCtD
Arformoterol—CYP2C9—Cisplatin—urinary bladder cancer	0.0386	0.161	CbGbCtD
Arformoterol—CYP2D6—Doxorubicin—urinary bladder cancer	0.0237	0.0987	CbGbCtD
Arformoterol—CYP2C19—urine—urinary bladder cancer	0.00594	0.202	CbGeAlD
Arformoterol—CYP2C9—urine—urinary bladder cancer	0.00461	0.157	CbGeAlD
Arformoterol—CYP2D6—urine—urinary bladder cancer	0.00346	0.118	CbGeAlD
Arformoterol—CYP2A6—prostate gland—urinary bladder cancer	0.00332	0.113	CbGeAlD
Arformoterol—CYP2A6—seminal vesicle—urinary bladder cancer	0.00281	0.0956	CbGeAlD
Arformoterol—ADRB1—prostate gland—urinary bladder cancer	0.00266	0.0908	CbGeAlD
Arformoterol—CYP2A6—vagina—urinary bladder cancer	0.00164	0.0558	CbGeAlD
Arformoterol—ADRB1—female reproductive system—urinary bladder cancer	0.00145	0.0495	CbGeAlD
Arformoterol—CYP2C19—vagina—urinary bladder cancer	0.00105	0.0359	CbGeAlD
Arformoterol—CYP2C9—female reproductive system—urinary bladder cancer	0.000903	0.0308	CbGeAlD
Arformoterol—CYP2D6—renal system—urinary bladder cancer	0.000846	0.0288	CbGeAlD
Arformoterol—CYP2D6—female reproductive system—urinary bladder cancer	0.000677	0.0231	CbGeAlD
Arformoterol—Nasopharyngitis—Doxorubicin—urinary bladder cancer	0.000634	0.00105	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000633	0.00105	CcSEcCtD
Arformoterol—Hypotension—Etoposide—urinary bladder cancer	0.000628	0.00104	CcSEcCtD
Arformoterol—Gastritis—Doxorubicin—urinary bladder cancer	0.000628	0.00104	CcSEcCtD
Arformoterol—Pain—Cisplatin—urinary bladder cancer	0.000627	0.00104	CcSEcCtD
Arformoterol—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000622	0.00103	CcSEcCtD
Arformoterol—Dizziness—Thiotepa—urinary bladder cancer	0.000619	0.00102	CcSEcCtD
Arformoterol—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.000616	0.00102	CcSEcCtD
Arformoterol—CYP2C19—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000615	0.00485	CbGpPWpGaD
Arformoterol—Urticaria—Fluorouracil—urinary bladder cancer	0.000615	0.00102	CcSEcCtD
Arformoterol—Conjunctivitis—Methotrexate—urinary bladder cancer	0.000613	0.00102	CcSEcCtD
Arformoterol—CYP2C9—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000613	0.00484	CbGpPWpGaD
Arformoterol—Influenza—Doxorubicin—urinary bladder cancer	0.000613	0.00101	CcSEcCtD
Arformoterol—Asthma—Doxorubicin—urinary bladder cancer	0.000613	0.00101	CcSEcCtD
Arformoterol—CYP2A6—Biological oxidations—NAT2—urinary bladder cancer	0.000613	0.00483	CbGpPWpGaD
Arformoterol—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000612	0.00101	CcSEcCtD
Arformoterol—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000604	0.001	CcSEcCtD
Arformoterol—Haematuria—Methotrexate—urinary bladder cancer	0.000602	0.000996	CcSEcCtD
Arformoterol—Dyspnoea—Etoposide—urinary bladder cancer	0.000599	0.000992	CcSEcCtD
Arformoterol—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.000598	0.000989	CcSEcCtD
Arformoterol—Somnolence—Etoposide—urinary bladder cancer	0.000597	0.000989	CcSEcCtD
Arformoterol—Angina pectoris—Doxorubicin—urinary bladder cancer	0.000597	0.000988	CcSEcCtD
Arformoterol—Vomiting—Thiotepa—urinary bladder cancer	0.000595	0.000985	CcSEcCtD
Arformoterol—Rash—Thiotepa—urinary bladder cancer	0.00059	0.000976	CcSEcCtD
Arformoterol—Bronchitis—Doxorubicin—urinary bladder cancer	0.000589	0.000976	CcSEcCtD
Arformoterol—Dermatitis—Thiotepa—urinary bladder cancer	0.000589	0.000975	CcSEcCtD
Arformoterol—Headache—Thiotepa—urinary bladder cancer	0.000586	0.00097	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.00058	0.00096	CcSEcCtD
Arformoterol—Body temperature increased—Cisplatin—urinary bladder cancer	0.00058	0.00096	CcSEcCtD
Arformoterol—Fatigue—Etoposide—urinary bladder cancer	0.000579	0.000959	CcSEcCtD
Arformoterol—Pain—Etoposide—urinary bladder cancer	0.000575	0.000951	CcSEcCtD
Arformoterol—Constipation—Etoposide—urinary bladder cancer	0.000575	0.000951	CcSEcCtD
Arformoterol—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000574	0.00095	CcSEcCtD
Arformoterol—Conjunctivitis—Epirubicin—urinary bladder cancer	0.000574	0.00095	CcSEcCtD
Arformoterol—CYP2D6—Biological oxidations—UGT2B7—urinary bladder cancer	0.000574	0.00453	CbGpPWpGaD
Arformoterol—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00057	0.000944	CcSEcCtD
Arformoterol—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.00057	0.000943	CcSEcCtD
Arformoterol—CYP2C9—Biological oxidations—UGT2B7—urinary bladder cancer	0.000569	0.00449	CbGpPWpGaD
Arformoterol—CYP2D6—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000566	0.00446	CbGpPWpGaD
Arformoterol—Asthenia—Gemcitabine—urinary bladder cancer	0.000565	0.000935	CcSEcCtD
Arformoterol—Haematuria—Epirubicin—urinary bladder cancer	0.000563	0.000932	CcSEcCtD
Arformoterol—Pharyngitis—Methotrexate—urinary bladder cancer	0.000562	0.000931	CcSEcCtD
Arformoterol—CYP2C19—Biological oxidations—CYP4B1—urinary bladder cancer	0.000561	0.00443	CbGpPWpGaD
Arformoterol—CYP2C9—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000561	0.00442	CbGpPWpGaD
Arformoterol—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000559	0.000926	CcSEcCtD
Arformoterol—Pruritus—Gemcitabine—urinary bladder cancer	0.000557	0.000922	CcSEcCtD
Arformoterol—Nausea—Thiotepa—urinary bladder cancer	0.000556	0.00092	CcSEcCtD
Arformoterol—Urethral disorder—Methotrexate—urinary bladder cancer	0.000555	0.000919	CcSEcCtD
Arformoterol—Sinusitis—Epirubicin—urinary bladder cancer	0.000554	0.000917	CcSEcCtD
Arformoterol—CYP2C19—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000554	0.00437	CbGpPWpGaD
Arformoterol—Feeling abnormal—Etoposide—urinary bladder cancer	0.000554	0.000917	CcSEcCtD
Arformoterol—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000553	0.000915	CcSEcCtD
Arformoterol—ADRB2—Arf6 signaling events—SRC—urinary bladder cancer	0.000552	0.00436	CbGpPWpGaD
Arformoterol—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000549	0.00091	CcSEcCtD
Arformoterol—Pruritus—Fluorouracil—urinary bladder cancer	0.000547	0.000906	CcSEcCtD
Arformoterol—Visual impairment—Methotrexate—urinary bladder cancer	0.000546	0.000904	CcSEcCtD
Arformoterol—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00054	0.000895	CcSEcCtD
Arformoterol—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000538	0.000891	CcSEcCtD
Arformoterol—Urticaria—Etoposide—urinary bladder cancer	0.000534	0.000884	CcSEcCtD
Arformoterol—Rhinitis—Epirubicin—urinary bladder cancer	0.000532	0.00088	CcSEcCtD
Arformoterol—Abdominal pain—Etoposide—urinary bladder cancer	0.000531	0.000879	CcSEcCtD
Arformoterol—Body temperature increased—Etoposide—urinary bladder cancer	0.000531	0.000879	CcSEcCtD
Arformoterol—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000531	0.000879	CcSEcCtD
Arformoterol—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000531	0.000879	CcSEcCtD
Arformoterol—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000529	0.000876	CcSEcCtD
Arformoterol—Asthenia—Cisplatin—urinary bladder cancer	0.000526	0.000871	CcSEcCtD
Arformoterol—Pharyngitis—Epirubicin—urinary bladder cancer	0.000526	0.000871	CcSEcCtD
Arformoterol—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000526	0.00087	CcSEcCtD
Arformoterol—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000524	0.000867	CcSEcCtD
Arformoterol—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000522	0.000865	CcSEcCtD
Arformoterol—Haematuria—Doxorubicin—urinary bladder cancer	0.000521	0.000862	CcSEcCtD
Arformoterol—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000521	0.000862	CcSEcCtD
Arformoterol—Urethral disorder—Epirubicin—urinary bladder cancer	0.00052	0.00086	CcSEcCtD
Arformoterol—CYP2D6—Biological oxidations—CYP4B1—urinary bladder cancer	0.000516	0.00407	CbGpPWpGaD
Arformoterol—Sinusitis—Doxorubicin—urinary bladder cancer	0.000513	0.000849	CcSEcCtD
Arformoterol—CYP2C9—Biological oxidations—CYP4B1—urinary bladder cancer	0.000512	0.00404	CbGpPWpGaD
Arformoterol—Immune system disorder—Methotrexate—urinary bladder cancer	0.000512	0.000847	CcSEcCtD
Arformoterol—Dizziness—Fluorouracil—urinary bladder cancer	0.000512	0.000847	CcSEcCtD
Arformoterol—Visual impairment—Epirubicin—urinary bladder cancer	0.000511	0.000846	CcSEcCtD
Arformoterol—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000511	0.000845	CcSEcCtD
Arformoterol—CYP2D6—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000509	0.00402	CbGpPWpGaD
Arformoterol—CYP2C9—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000505	0.00398	CbGpPWpGaD
Arformoterol—Diarrhoea—Cisplatin—urinary bladder cancer	0.000502	0.000831	CcSEcCtD
Arformoterol—Vomiting—Gemcitabine—urinary bladder cancer	0.0005	0.000828	CcSEcCtD
Arformoterol—Mental disorder—Methotrexate—urinary bladder cancer	0.000496	0.000822	CcSEcCtD
Arformoterol—Rash—Gemcitabine—urinary bladder cancer	0.000496	0.000821	CcSEcCtD
Arformoterol—Dermatitis—Gemcitabine—urinary bladder cancer	0.000496	0.000821	CcSEcCtD
Arformoterol—Hypersensitivity—Etoposide—urinary bladder cancer	0.000495	0.00082	CcSEcCtD
Arformoterol—Malnutrition—Methotrexate—urinary bladder cancer	0.000493	0.000816	CcSEcCtD
Arformoterol—Headache—Gemcitabine—urinary bladder cancer	0.000493	0.000816	CcSEcCtD
Arformoterol—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000492	0.000815	CcSEcCtD
Arformoterol—Vomiting—Fluorouracil—urinary bladder cancer	0.000492	0.000814	CcSEcCtD
Arformoterol—Rhinitis—Doxorubicin—urinary bladder cancer	0.000492	0.000814	CcSEcCtD
Arformoterol—CYP2A6—Biological oxidations—HPGDS—urinary bladder cancer	0.00049	0.00387	CbGpPWpGaD
Arformoterol—Rash—Fluorouracil—urinary bladder cancer	0.000488	0.000808	CcSEcCtD
Arformoterol—Dermatitis—Fluorouracil—urinary bladder cancer	0.000487	0.000807	CcSEcCtD
Arformoterol—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000487	0.000806	CcSEcCtD
Arformoterol—Headache—Fluorouracil—urinary bladder cancer	0.000485	0.000802	CcSEcCtD
Arformoterol—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000484	0.000802	CcSEcCtD
Arformoterol—ADRB2—Arf6 signaling events—EGFR—urinary bladder cancer	0.000484	0.00382	CbGpPWpGaD
Arformoterol—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000483	0.0008	CcSEcCtD
Arformoterol—Dysgeusia—Methotrexate—urinary bladder cancer	0.000483	0.000799	CcSEcCtD
Arformoterol—Asthenia—Etoposide—urinary bladder cancer	0.000482	0.000798	CcSEcCtD
Arformoterol—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000482	0.000798	CcSEcCtD
Arformoterol—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000481	0.000796	CcSEcCtD
Arformoterol—Immune system disorder—Epirubicin—urinary bladder cancer	0.000479	0.000793	CcSEcCtD
Arformoterol—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000478	0.000791	CcSEcCtD
Arformoterol—Back pain—Methotrexate—urinary bladder cancer	0.000477	0.00079	CcSEcCtD
Arformoterol—Pruritus—Etoposide—urinary bladder cancer	0.000475	0.000787	CcSEcCtD
Arformoterol—CYP2A6—Biological oxidations—GSTT1—urinary bladder cancer	0.000475	0.00375	CbGpPWpGaD
Arformoterol—CYP2C19—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000475	0.00375	CbGpPWpGaD
Arformoterol—Arrhythmia—Epirubicin—urinary bladder cancer	0.000474	0.000784	CcSEcCtD
Arformoterol—Visual impairment—Doxorubicin—urinary bladder cancer	0.000473	0.000783	CcSEcCtD
Arformoterol—Nausea—Gemcitabine—urinary bladder cancer	0.000467	0.000774	CcSEcCtD
Arformoterol—Vomiting—Cisplatin—urinary bladder cancer	0.000466	0.000772	CcSEcCtD
Arformoterol—Mental disorder—Epirubicin—urinary bladder cancer	0.000464	0.000769	CcSEcCtD
Arformoterol—Rash—Cisplatin—urinary bladder cancer	0.000462	0.000766	CcSEcCtD
Arformoterol—Dermatitis—Cisplatin—urinary bladder cancer	0.000462	0.000765	CcSEcCtD
Arformoterol—Malnutrition—Epirubicin—urinary bladder cancer	0.000462	0.000764	CcSEcCtD
Arformoterol—Diarrhoea—Etoposide—urinary bladder cancer	0.00046	0.000761	CcSEcCtD
Arformoterol—Nausea—Fluorouracil—urinary bladder cancer	0.00046	0.000761	CcSEcCtD
Arformoterol—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000458	0.000757	CcSEcCtD
Arformoterol—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000455	0.000754	CcSEcCtD
Arformoterol—Tension—Epirubicin—urinary bladder cancer	0.000453	0.00075	CcSEcCtD
Arformoterol—Dysgeusia—Epirubicin—urinary bladder cancer	0.000452	0.000748	CcSEcCtD
Arformoterol—CYP2A6—NRF2 pathway—NQO1—urinary bladder cancer	0.00045	0.00355	CbGpPWpGaD
Arformoterol—Nervousness—Epirubicin—urinary bladder cancer	0.000448	0.000742	CcSEcCtD
Arformoterol—Back pain—Epirubicin—urinary bladder cancer	0.000446	0.000739	CcSEcCtD
Arformoterol—Malaise—Methotrexate—urinary bladder cancer	0.000445	0.000736	CcSEcCtD
Arformoterol—Dizziness—Etoposide—urinary bladder cancer	0.000444	0.000736	CcSEcCtD
Arformoterol—Muscle spasms—Epirubicin—urinary bladder cancer	0.000444	0.000735	CcSEcCtD
Arformoterol—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000443	0.000733	CcSEcCtD
Arformoterol—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000442	0.000732	CcSEcCtD
Arformoterol—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000441	0.00348	CbGpPWpGaD
Arformoterol—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000438	0.000725	CcSEcCtD
Arformoterol—Nausea—Cisplatin—urinary bladder cancer	0.000436	0.000721	CcSEcCtD
Arformoterol—CYP2C9—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000433	0.00342	CbGpPWpGaD
Arformoterol—Cough—Methotrexate—urinary bladder cancer	0.00043	0.000712	CcSEcCtD
Arformoterol—Mental disorder—Doxorubicin—urinary bladder cancer	0.00043	0.000711	CcSEcCtD
Arformoterol—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000428	0.000709	CcSEcCtD
Arformoterol—Vomiting—Etoposide—urinary bladder cancer	0.000427	0.000707	CcSEcCtD
Arformoterol—Malnutrition—Doxorubicin—urinary bladder cancer	0.000427	0.000707	CcSEcCtD
Arformoterol—Agitation—Epirubicin—urinary bladder cancer	0.000424	0.000702	CcSEcCtD
Arformoterol—Rash—Etoposide—urinary bladder cancer	0.000424	0.000701	CcSEcCtD
Arformoterol—Dermatitis—Etoposide—urinary bladder cancer	0.000423	0.000701	CcSEcCtD
Arformoterol—Headache—Etoposide—urinary bladder cancer	0.000421	0.000697	CcSEcCtD
Arformoterol—Myalgia—Methotrexate—urinary bladder cancer	0.00042	0.000695	CcSEcCtD
Arformoterol—Arthralgia—Methotrexate—urinary bladder cancer	0.00042	0.000695	CcSEcCtD
Arformoterol—Chest pain—Methotrexate—urinary bladder cancer	0.00042	0.000695	CcSEcCtD
Arformoterol—Tension—Doxorubicin—urinary bladder cancer	0.000419	0.000694	CcSEcCtD
Arformoterol—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000418	0.000692	CcSEcCtD
Arformoterol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000417	0.00069	CcSEcCtD
Arformoterol—Malaise—Epirubicin—urinary bladder cancer	0.000416	0.000689	CcSEcCtD
Arformoterol—Discomfort—Methotrexate—urinary bladder cancer	0.000415	0.000687	CcSEcCtD
Arformoterol—Nervousness—Doxorubicin—urinary bladder cancer	0.000415	0.000687	CcSEcCtD
Arformoterol—Back pain—Doxorubicin—urinary bladder cancer	0.000413	0.000684	CcSEcCtD
Arformoterol—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000411	0.00068	CcSEcCtD
Arformoterol—Palpitations—Epirubicin—urinary bladder cancer	0.000408	0.000675	CcSEcCtD
Arformoterol—Cough—Epirubicin—urinary bladder cancer	0.000403	0.000667	CcSEcCtD
Arformoterol—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000403	0.000666	CcSEcCtD
Arformoterol—Infection—Methotrexate—urinary bladder cancer	0.0004	0.000662	CcSEcCtD
Arformoterol—Nausea—Etoposide—urinary bladder cancer	0.000399	0.000661	CcSEcCtD
Arformoterol—Hypertension—Epirubicin—urinary bladder cancer	0.000398	0.00066	CcSEcCtD
Arformoterol—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000396	0.000656	CcSEcCtD
Arformoterol—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000395	0.000653	CcSEcCtD
Arformoterol—Arthralgia—Epirubicin—urinary bladder cancer	0.000393	0.00065	CcSEcCtD
Arformoterol—Chest pain—Epirubicin—urinary bladder cancer	0.000393	0.00065	CcSEcCtD
Arformoterol—Myalgia—Epirubicin—urinary bladder cancer	0.000393	0.00065	CcSEcCtD
Arformoterol—Agitation—Doxorubicin—urinary bladder cancer	0.000392	0.00065	CcSEcCtD
Arformoterol—Anxiety—Epirubicin—urinary bladder cancer	0.000392	0.000648	CcSEcCtD
Arformoterol—Skin disorder—Methotrexate—urinary bladder cancer	0.000391	0.000647	CcSEcCtD
Arformoterol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.00039	0.000646	CcSEcCtD
Arformoterol—Discomfort—Epirubicin—urinary bladder cancer	0.000388	0.000643	CcSEcCtD
Arformoterol—Malaise—Doxorubicin—urinary bladder cancer	0.000385	0.000637	CcSEcCtD
Arformoterol—Dry mouth—Epirubicin—urinary bladder cancer	0.000384	0.000636	CcSEcCtD
Arformoterol—CYP2A6—Fluoropyrimidine Activity—TP53—urinary bladder cancer	0.00038	0.003	CbGpPWpGaD
Arformoterol—Palpitations—Doxorubicin—urinary bladder cancer	0.000377	0.000625	CcSEcCtD
Arformoterol—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000377	0.000624	CcSEcCtD
Arformoterol—Oedema—Epirubicin—urinary bladder cancer	0.000377	0.000624	CcSEcCtD
Arformoterol—Hypotension—Methotrexate—urinary bladder cancer	0.000376	0.000623	CcSEcCtD
Arformoterol—CYP2A6—NRF2 pathway—GSTP1—urinary bladder cancer	0.000375	0.00296	CbGpPWpGaD
Arformoterol—Infection—Epirubicin—urinary bladder cancer	0.000374	0.000619	CcSEcCtD
Arformoterol—CYP2C19—Biological oxidations—NAT2—urinary bladder cancer	0.000374	0.00295	CbGpPWpGaD
Arformoterol—Cough—Doxorubicin—urinary bladder cancer	0.000373	0.000617	CcSEcCtD
Arformoterol—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000369	0.000611	CcSEcCtD
Arformoterol—Hypertension—Doxorubicin—urinary bladder cancer	0.000369	0.00061	CcSEcCtD
Arformoterol—CYP2C19—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000368	0.00291	CbGpPWpGaD
Arformoterol—Tachycardia—Epirubicin—urinary bladder cancer	0.000368	0.000609	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000367	0.000607	CcSEcCtD
Arformoterol—Skin disorder—Epirubicin—urinary bladder cancer	0.000366	0.000606	CcSEcCtD
Arformoterol—Insomnia—Methotrexate—urinary bladder cancer	0.000364	0.000603	CcSEcCtD
Arformoterol—Arthralgia—Doxorubicin—urinary bladder cancer	0.000364	0.000602	CcSEcCtD
Arformoterol—Myalgia—Doxorubicin—urinary bladder cancer	0.000364	0.000602	CcSEcCtD
Arformoterol—Chest pain—Doxorubicin—urinary bladder cancer	0.000364	0.000602	CcSEcCtD
Arformoterol—Anxiety—Doxorubicin—urinary bladder cancer	0.000362	0.0006	CcSEcCtD
Arformoterol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000361	0.000598	CcSEcCtD
Arformoterol—Discomfort—Doxorubicin—urinary bladder cancer	0.000359	0.000595	CcSEcCtD
Arformoterol—Dyspnoea—Methotrexate—urinary bladder cancer	0.000359	0.000594	CcSEcCtD
Arformoterol—Somnolence—Methotrexate—urinary bladder cancer	0.000358	0.000592	CcSEcCtD
Arformoterol—Dry mouth—Doxorubicin—urinary bladder cancer	0.000356	0.000589	CcSEcCtD
Arformoterol—Dyspepsia—Methotrexate—urinary bladder cancer	0.000354	0.000586	CcSEcCtD
Arformoterol—Hypotension—Epirubicin—urinary bladder cancer	0.000352	0.000583	CcSEcCtD
Arformoterol—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000349	0.000577	CcSEcCtD
Arformoterol—Oedema—Doxorubicin—urinary bladder cancer	0.000349	0.000577	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000347	0.000575	CcSEcCtD
Arformoterol—Fatigue—Methotrexate—urinary bladder cancer	0.000347	0.000574	CcSEcCtD
Arformoterol—Infection—Doxorubicin—urinary bladder cancer	0.000346	0.000573	CcSEcCtD
Arformoterol—CYP2A6—NRF2 pathway—GSTM1—urinary bladder cancer	0.000345	0.00272	CbGpPWpGaD
Arformoterol—Pain—Methotrexate—urinary bladder cancer	0.000344	0.00057	CcSEcCtD
Arformoterol—CYP2D6—Biological oxidations—NAT2—urinary bladder cancer	0.000344	0.00271	CbGpPWpGaD
Arformoterol—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000343	0.000568	CcSEcCtD
Arformoterol—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000342	0.000566	CcSEcCtD
Arformoterol—Insomnia—Epirubicin—urinary bladder cancer	0.000341	0.000564	CcSEcCtD
Arformoterol—CYP2C9—Biological oxidations—NAT2—urinary bladder cancer	0.000341	0.00269	CbGpPWpGaD
Arformoterol—Tachycardia—Doxorubicin—urinary bladder cancer	0.00034	0.000563	CcSEcCtD
Arformoterol—CYP2D6—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000339	0.00267	CbGpPWpGaD
Arformoterol—Skin disorder—Doxorubicin—urinary bladder cancer	0.000339	0.00056	CcSEcCtD
Arformoterol—CYP2C9—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000336	0.00265	CbGpPWpGaD
Arformoterol—Dyspnoea—Epirubicin—urinary bladder cancer	0.000336	0.000556	CcSEcCtD
Arformoterol—Somnolence—Epirubicin—urinary bladder cancer	0.000335	0.000554	CcSEcCtD
Arformoterol—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000332	0.000549	CcSEcCtD
Arformoterol—Dyspepsia—Epirubicin—urinary bladder cancer	0.000332	0.000549	CcSEcCtD
Arformoterol—CYP2A6—Biological oxidations—GSTP1—urinary bladder cancer	0.000329	0.0026	CbGpPWpGaD
Arformoterol—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000329	0.000545	CcSEcCtD
Arformoterol—Hypotension—Doxorubicin—urinary bladder cancer	0.000326	0.000539	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000325	0.000538	CcSEcCtD
Arformoterol—Fatigue—Epirubicin—urinary bladder cancer	0.000325	0.000538	CcSEcCtD
Arformoterol—Constipation—Epirubicin—urinary bladder cancer	0.000322	0.000533	CcSEcCtD
Arformoterol—Pain—Epirubicin—urinary bladder cancer	0.000322	0.000533	CcSEcCtD
Arformoterol—Urticaria—Methotrexate—urinary bladder cancer	0.00032	0.000529	CcSEcCtD
Arformoterol—Abdominal pain—Methotrexate—urinary bladder cancer	0.000318	0.000527	CcSEcCtD
Arformoterol—Body temperature increased—Methotrexate—urinary bladder cancer	0.000318	0.000527	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000318	0.000526	CcSEcCtD
Arformoterol—Insomnia—Doxorubicin—urinary bladder cancer	0.000315	0.000522	CcSEcCtD
Arformoterol—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000311	0.000514	CcSEcCtD
Arformoterol—Feeling abnormal—Epirubicin—urinary bladder cancer	0.00031	0.000514	CcSEcCtD
Arformoterol—Somnolence—Doxorubicin—urinary bladder cancer	0.00031	0.000513	CcSEcCtD
Arformoterol—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000308	0.00051	CcSEcCtD
Arformoterol—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000307	0.000508	CcSEcCtD
Arformoterol—CYP2A6—Biological oxidations—GSTM1—urinary bladder cancer	0.000303	0.00239	CbGpPWpGaD
Arformoterol—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000301	0.000498	CcSEcCtD
Arformoterol—Fatigue—Doxorubicin—urinary bladder cancer	0.0003	0.000497	CcSEcCtD
Arformoterol—Urticaria—Epirubicin—urinary bladder cancer	0.000299	0.000495	CcSEcCtD
Arformoterol—CYP2C19—Biological oxidations—HPGDS—urinary bladder cancer	0.000299	0.00236	CbGpPWpGaD
Arformoterol—Constipation—Doxorubicin—urinary bladder cancer	0.000298	0.000493	CcSEcCtD
Arformoterol—Pain—Doxorubicin—urinary bladder cancer	0.000298	0.000493	CcSEcCtD
Arformoterol—Body temperature increased—Epirubicin—urinary bladder cancer	0.000298	0.000493	CcSEcCtD
Arformoterol—Abdominal pain—Epirubicin—urinary bladder cancer	0.000298	0.000493	CcSEcCtD
Arformoterol—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000297	0.000491	CcSEcCtD
Arformoterol—CYP2C19—Biological oxidations—GSTT1—urinary bladder cancer	0.00029	0.00229	CbGpPWpGaD
Arformoterol—Asthenia—Methotrexate—urinary bladder cancer	0.000289	0.000478	CcSEcCtD
Arformoterol—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000287	0.000475	CcSEcCtD
Arformoterol—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000285	0.000472	CcSEcCtD
Arformoterol—Pruritus—Methotrexate—urinary bladder cancer	0.000285	0.000471	CcSEcCtD
Arformoterol—CYP2C19—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000279	0.00221	CbGpPWpGaD
Arformoterol—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000278	0.000459	CcSEcCtD
Arformoterol—Urticaria—Doxorubicin—urinary bladder cancer	0.000277	0.000458	CcSEcCtD
Arformoterol—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000276	0.000456	CcSEcCtD
Arformoterol—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000276	0.000456	CcSEcCtD
Arformoterol—Diarrhoea—Methotrexate—urinary bladder cancer	0.000275	0.000456	CcSEcCtD
Arformoterol—CYP2D6—Biological oxidations—HPGDS—urinary bladder cancer	0.000275	0.00217	CbGpPWpGaD
Arformoterol—CYP2C9—Biological oxidations—HPGDS—urinary bladder cancer	0.000272	0.00215	CbGpPWpGaD
Arformoterol—Asthenia—Epirubicin—urinary bladder cancer	0.00027	0.000447	CcSEcCtD
Arformoterol—Pruritus—Epirubicin—urinary bladder cancer	0.000266	0.000441	CcSEcCtD
Arformoterol—CYP2D6—Biological oxidations—GSTT1—urinary bladder cancer	0.000266	0.0021	CbGpPWpGaD
Arformoterol—Dizziness—Methotrexate—urinary bladder cancer	0.000266	0.000441	CcSEcCtD
Arformoterol—CYP2C9—Biological oxidations—GSTT1—urinary bladder cancer	0.000264	0.00208	CbGpPWpGaD
Arformoterol—Diarrhoea—Epirubicin—urinary bladder cancer	0.000258	0.000427	CcSEcCtD
Arformoterol—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000257	0.000425	CcSEcCtD
Arformoterol—Vomiting—Methotrexate—urinary bladder cancer	0.000256	0.000424	CcSEcCtD
Arformoterol—CYP2C9—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000255	0.00201	CbGpPWpGaD
Arformoterol—Rash—Methotrexate—urinary bladder cancer	0.000254	0.00042	CcSEcCtD
Arformoterol—Dermatitis—Methotrexate—urinary bladder cancer	0.000254	0.00042	CcSEcCtD
Arformoterol—Headache—Methotrexate—urinary bladder cancer	0.000252	0.000417	CcSEcCtD
Arformoterol—Asthenia—Doxorubicin—urinary bladder cancer	0.00025	0.000414	CcSEcCtD
Arformoterol—Dizziness—Epirubicin—urinary bladder cancer	0.000249	0.000412	CcSEcCtD
Arformoterol—Pruritus—Doxorubicin—urinary bladder cancer	0.000247	0.000408	CcSEcCtD
Arformoterol—Vomiting—Epirubicin—urinary bladder cancer	0.000239	0.000396	CcSEcCtD
Arformoterol—Nausea—Methotrexate—urinary bladder cancer	0.000239	0.000396	CcSEcCtD
Arformoterol—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000238	0.000395	CcSEcCtD
Arformoterol—Rash—Epirubicin—urinary bladder cancer	0.000238	0.000393	CcSEcCtD
Arformoterol—Dermatitis—Epirubicin—urinary bladder cancer	0.000237	0.000393	CcSEcCtD
Arformoterol—Headache—Epirubicin—urinary bladder cancer	0.000236	0.000391	CcSEcCtD
Arformoterol—Dizziness—Doxorubicin—urinary bladder cancer	0.00023	0.000382	CcSEcCtD
Arformoterol—Nausea—Epirubicin—urinary bladder cancer	0.000224	0.00037	CcSEcCtD
Arformoterol—Vomiting—Doxorubicin—urinary bladder cancer	0.000222	0.000367	CcSEcCtD
Arformoterol—Rash—Doxorubicin—urinary bladder cancer	0.00022	0.000364	CcSEcCtD
Arformoterol—Dermatitis—Doxorubicin—urinary bladder cancer	0.00022	0.000363	CcSEcCtD
Arformoterol—Headache—Doxorubicin—urinary bladder cancer	0.000218	0.000361	CcSEcCtD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000216	0.0017	CbGpPWpGaD
Arformoterol—Nausea—Doxorubicin—urinary bladder cancer	0.000207	0.000343	CcSEcCtD
Arformoterol—CYP2A6—Metabolism—GSTZ1—urinary bladder cancer	0.000202	0.00159	CbGpPWpGaD
Arformoterol—CYP2C19—Biological oxidations—GSTP1—urinary bladder cancer	0.000201	0.00158	CbGpPWpGaD
Arformoterol—CYP2C19—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000198	0.00156	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000197	0.00155	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—GSTO2—urinary bladder cancer	0.000191	0.00151	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—NAT1—urinary bladder cancer	0.000191	0.00151	CbGpPWpGaD
Arformoterol—CYP2D6—Biological oxidations—GSTP1—urinary bladder cancer	0.000185	0.00146	CbGpPWpGaD
Arformoterol—CYP2C19—Biological oxidations—GSTM1—urinary bladder cancer	0.000185	0.00146	CbGpPWpGaD
Arformoterol—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	0.000183	0.00144	CbGpPWpGaD
Arformoterol—CYP2D6—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000182	0.00144	CbGpPWpGaD
Arformoterol—CYP2C19—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000182	0.00144	CbGpPWpGaD
Arformoterol—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000181	0.00142	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—UGT2B7—urinary bladder cancer	0.000175	0.00138	CbGpPWpGaD
Arformoterol—CYP2D6—Biological oxidations—GSTM1—urinary bladder cancer	0.00017	0.00134	CbGpPWpGaD
Arformoterol—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	0.000168	0.00133	CbGpPWpGaD
Arformoterol—CYP2D6—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000167	0.00132	CbGpPWpGaD
Arformoterol—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000166	0.00131	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—CYP4B1—urinary bladder cancer	0.000157	0.00124	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—SLC19A1—urinary bladder cancer	0.000149	0.00117	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PRSS3—urinary bladder cancer	0.000145	0.00114	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—HDAC4—urinary bladder cancer	0.000132	0.00104	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—HDAC4—urinary bladder cancer	0.000129	0.00102	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GSTZ1—urinary bladder cancer	0.000123	0.000971	CbGpPWpGaD
Arformoterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	0.000117	0.000926	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GSTO2—urinary bladder cancer	0.000117	0.00092	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—NAT1—urinary bladder cancer	0.000117	0.00092	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—TYMP—urinary bladder cancer	0.000116	0.000914	CbGpPWpGaD
Arformoterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	0.000115	0.000906	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000115	0.000905	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GSTZ1—urinary bladder cancer	0.000113	0.000893	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	0.000112	0.000885	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—GLI1—urinary bladder cancer	0.000111	0.000875	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—GLI1—urinary bladder cancer	0.000108	0.000856	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	0.000107	0.000846	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—NAT1—urinary bladder cancer	0.000107	0.000846	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—UGT2B7—urinary bladder cancer	0.000107	0.000841	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	0.000106	0.000839	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—NAT1—urinary bladder cancer	0.000106	0.000839	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—NAT2—urinary bladder cancer	0.000105	0.000827	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000105	0.000825	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	9.81e-05	0.000774	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	9.72e-05	0.000767	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CYP4B1—urinary bladder cancer	9.6e-05	0.000758	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—SLC19A1—urinary bladder cancer	9.07e-05	0.000715	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—RRM2—urinary bladder cancer	9.05e-05	0.000714	CbGpPWpGaD
Arformoterol—ADRB1—GPCR ligand binding—CXCL8—urinary bladder cancer	8.93e-05	0.000705	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PRSS3—urinary bladder cancer	8.84e-05	0.000697	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	8.83e-05	0.000697	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	8.76e-05	0.000691	CbGpPWpGaD
Arformoterol—ADRB2—GPCR ligand binding—CXCL8—urinary bladder cancer	8.74e-05	0.00069	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—ENO2—urinary bladder cancer	8.38e-05	0.000661	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—HPGDS—urinary bladder cancer	8.38e-05	0.000661	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	8.34e-05	0.000658	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	8.27e-05	0.000652	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	8.13e-05	0.000641	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—GSTT1—urinary bladder cancer	8.13e-05	0.000641	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	8.06e-05	0.000636	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—RBX1—urinary bladder cancer	7.6e-05	0.0006	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—RBX1—urinary bladder cancer	7.44e-05	0.000587	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—TSC1—urinary bladder cancer	7.15e-05	0.000564	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	7.09e-05	0.000559	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—TYMP—urinary bladder cancer	7.06e-05	0.000557	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—TSC1—urinary bladder cancer	6.99e-05	0.000552	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—JAG1—urinary bladder cancer	6.8e-05	0.000537	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	6.79e-05	0.000535	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—NQO1—urinary bladder cancer	6.75e-05	0.000533	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—JAG1—urinary bladder cancer	6.66e-05	0.000525	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—TYMP—urinary bladder cancer	6.5e-05	0.000513	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	6.46e-05	0.00051	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—TYMP—urinary bladder cancer	6.44e-05	0.000508	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—NAT2—urinary bladder cancer	6.39e-05	0.000504	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	6.19e-05	0.000488	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—NAT2—urinary bladder cancer	5.88e-05	0.000464	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—NAT2—urinary bladder cancer	5.83e-05	0.00046	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—RHOA—urinary bladder cancer	5.75e-05	0.000454	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—GSTP1—urinary bladder cancer	5.63e-05	0.000444	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—RHOA—urinary bladder cancer	5.63e-05	0.000444	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—RRM2—urinary bladder cancer	5.52e-05	0.000435	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—S100B—urinary bladder cancer	5.51e-05	0.000435	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—S100B—urinary bladder cancer	5.39e-05	0.000425	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—TYMS—urinary bladder cancer	5.24e-05	0.000413	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—RHOA—urinary bladder cancer	5.22e-05	0.000412	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—NCOR1—urinary bladder cancer	5.18e-05	0.000408	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—GSTM1—urinary bladder cancer	5.18e-05	0.000408	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—RHOA—urinary bladder cancer	5.11e-05	0.000403	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	5.11e-05	0.000403	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—ENO2—urinary bladder cancer	5.11e-05	0.000403	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	5.08e-05	0.000401	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—RRM2—urinary bladder cancer	5.07e-05	0.0004	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—CXCL8—urinary bladder cancer	5.05e-05	0.000398	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—RRM2—urinary bladder cancer	5.03e-05	0.000397	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—GPX1—urinary bladder cancer	4.96e-05	0.000391	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	4.95e-05	0.000391	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—NCOR1—urinary bladder cancer	4.95e-05	0.000391	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—CXCL8—urinary bladder cancer	4.94e-05	0.00039	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.88e-05	0.000385	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—ERCC2—urinary bladder cancer	4.87e-05	0.000384	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—NCOR1—urinary bladder cancer	4.85e-05	0.000382	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—IL2—urinary bladder cancer	4.83e-05	0.000381	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—IL2—urinary bladder cancer	4.72e-05	0.000372	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	4.7e-05	0.000371	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—ENO2—urinary bladder cancer	4.7e-05	0.000371	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	4.66e-05	0.000367	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—ENO2—urinary bladder cancer	4.66e-05	0.000367	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.63e-05	0.000365	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—CXCL8—urinary bladder cancer	4.59e-05	0.000362	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—MTHFR—urinary bladder cancer	4.57e-05	0.000361	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	4.56e-05	0.00036	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	4.52e-05	0.000356	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—CXCL8—urinary bladder cancer	4.49e-05	0.000354	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.45e-05	0.000351	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—IL2—urinary bladder cancer	4.38e-05	0.000346	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—TERT—urinary bladder cancer	4.37e-05	0.000344	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—IL2—urinary bladder cancer	4.29e-05	0.000338	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—TERT—urinary bladder cancer	4.27e-05	0.000337	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—NQO1—urinary bladder cancer	4.12e-05	0.000325	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—FGFR3—urinary bladder cancer	4.01e-05	0.000316	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.99e-05	0.000315	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—FGFR3—urinary bladder cancer	3.92e-05	0.000309	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—ESR1—urinary bladder cancer	3.89e-05	0.000307	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—ESR1—urinary bladder cancer	3.81e-05	0.0003	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—NQO1—urinary bladder cancer	3.79e-05	0.000299	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—NQO1—urinary bladder cancer	3.75e-05	0.000296	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PPARG—urinary bladder cancer	3.71e-05	0.000293	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.64e-05	0.000287	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—CREBBP—urinary bladder cancer	3.56e-05	0.000281	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.48e-05	0.000275	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	3.43e-05	0.000271	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CREBBP—urinary bladder cancer	3.41e-05	0.000269	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—IGF1—urinary bladder cancer	3.37e-05	0.000266	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—EGFR—urinary bladder cancer	3.35e-05	0.000264	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CREBBP—urinary bladder cancer	3.34e-05	0.000263	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.32e-05	0.000262	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—IGF1—urinary bladder cancer	3.29e-05	0.00026	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—EGFR—urinary bladder cancer	3.28e-05	0.000259	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—TYMS—urinary bladder cancer	3.19e-05	0.000252	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.18e-05	0.000251	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—KRAS—urinary bladder cancer	3.17e-05	0.00025	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	3.16e-05	0.000249	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	3.16e-05	0.000249	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	3.16e-05	0.000249	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	3.13e-05	0.000247	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—KRAS—urinary bladder cancer	3.1e-05	0.000244	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—RHOA—urinary bladder cancer	3.09e-05	0.000243	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.03e-05	0.000239	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GPX1—urinary bladder cancer	3.02e-05	0.000238	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—RHOA—urinary bladder cancer	3.02e-05	0.000238	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	2.97e-05	0.000234	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—TYMS—urinary bladder cancer	2.94e-05	0.000232	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PTGS2—urinary bladder cancer	2.92e-05	0.00023	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—TYMS—urinary bladder cancer	2.91e-05	0.00023	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	2.9e-05	0.000229	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	2.9e-05	0.000229	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	2.88e-05	0.000227	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	2.88e-05	0.000227	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—ERBB2—urinary bladder cancer	2.86e-05	0.000225	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—ERBB2—urinary bladder cancer	2.79e-05	0.00022	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	2.79e-05	0.00022	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GPX1—urinary bladder cancer	2.78e-05	0.000219	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GPX1—urinary bladder cancer	2.76e-05	0.000217	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	2.73e-05	0.000215	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CXCL8—urinary bladder cancer	2.71e-05	0.000214	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	2.71e-05	0.000213	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—HRAS—urinary bladder cancer	2.69e-05	0.000212	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CXCL8—urinary bladder cancer	2.65e-05	0.000209	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—HRAS—urinary bladder cancer	2.63e-05	0.000208	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—IL2—urinary bladder cancer	2.59e-05	0.000204	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	2.56e-05	0.000202	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PTEN—urinary bladder cancer	2.54e-05	0.000201	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	2.54e-05	0.000201	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—IL2—urinary bladder cancer	2.53e-05	0.0002	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CCND1—urinary bladder cancer	2.52e-05	0.000199	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CCND1—urinary bladder cancer	2.47e-05	0.000195	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MMP9—urinary bladder cancer	2.45e-05	0.000193	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CDKN1A—urinary bladder cancer	2.44e-05	0.000193	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PTEN—urinary bladder cancer	2.44e-05	0.000192	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—EP300—urinary bladder cancer	2.43e-05	0.000191	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MMP9—urinary bladder cancer	2.4e-05	0.000189	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CDKN1A—urinary bladder cancer	2.39e-05	0.000188	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PTEN—urinary bladder cancer	2.38e-05	0.000188	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—EP300—urinary bladder cancer	2.32e-05	0.000183	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—EP300—urinary bladder cancer	2.27e-05	0.000179	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PPARG—urinary bladder cancer	2.26e-05	0.000178	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—SRC—urinary bladder cancer	2.26e-05	0.000178	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—SRC—urinary bladder cancer	2.21e-05	0.000174	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	2.17e-05	0.000171	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PPARG—urinary bladder cancer	2.08e-05	0.000164	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PPARG—urinary bladder cancer	2.06e-05	0.000163	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MYC—urinary bladder cancer	2.02e-05	0.00016	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	2e-05	0.000158	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	1.98e-05	0.000156	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MYC—urinary bladder cancer	1.98e-05	0.000156	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—EGFR—urinary bladder cancer	1.98e-05	0.000156	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—EGFR—urinary bladder cancer	1.94e-05	0.000153	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—KRAS—urinary bladder cancer	1.87e-05	0.000148	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—KRAS—urinary bladder cancer	1.83e-05	0.000144	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	1.78e-05	0.00014	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—TP53—urinary bladder cancer	1.66e-05	0.000131	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	1.64e-05	0.000129	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—TP53—urinary bladder cancer	1.63e-05	0.000128	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	1.62e-05	0.000128	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—HRAS—urinary bladder cancer	1.59e-05	0.000125	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—HRAS—urinary bladder cancer	1.56e-05	0.000123	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PTEN—urinary bladder cancer	1.55e-05	0.000122	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—EP300—urinary bladder cancer	1.48e-05	0.000117	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PTEN—urinary bladder cancer	1.43e-05	0.000113	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PTEN—urinary bladder cancer	1.41e-05	0.000112	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—EP300—urinary bladder cancer	1.36e-05	0.000107	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—EP300—urinary bladder cancer	1.35e-05	0.000106	CbGpPWpGaD
